Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
Status:
Unknown status
Trial end date:
2020-03-02
Target enrollment:
Participant gender:
Summary
This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original
zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China.
Four hundred and sixty-six subjects will be randomised (1:1ratio) to either Yigu® 5mg IV or
Aclasta® 5mg IV treatment arms.
Phase:
Phase 4
Details
Lead Sponsor:
Cttq
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Vitamin D Vitamins Zoledronic Acid